Immunochemical analysis of cathepsin B in lung tumours: An independent prognostic factor for squamous cell carcinoma patients

British Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 510-519

  Werle, B ^a   Lotterle H ^a   Schanzenbacher U ^a   Lah, T T ^d   Kalman, E ^e   Kayser, K ^b   Bulzebruck H ^c   Schirren, J ^b   Krasovec, M ^f   Kos, J ^f,g   Spiess, E ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Abteilung Pathologie   (Germany)

^c Abt F Statistische Dokumentation   (Germany)

^d NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^e UNIVERSITY OF PÉCS   (Hungary)

^f JO EF STEFAN INSTITUTE   (Slovenia)

^g KRKA D D   (Slovenia)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cathepsin B; Non small cell lung cancer; Prognosis; Squamous cell carcinoma

Indexed keywords

CATHEPSIN B;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; ENZYME ACTIVITY; FEMALE; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; LUNG TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PH; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CATHEPSIN B; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032872258     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690723     Document Type: Article

References (61)

1. Abel U, Berger J and Wiebelt H (1984) Critlevel. An exploratory procedure for the evaluation of quantitative prognustic factors. Methods Inf Med 23: 154-156
2. Berquin IM and Sloane BF (1995) Cysteine proteases and tumor progression. Perspect Drug Discovery Design 2: 371-388
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
4. Budihna M, Strojan P, Šmid L, Škrk J, Vrhovec I. Zupeve A, Rudolf Z. Zargi M, Krasovec M, Svetic B, Kopilar Jerala N and Kos J (1996) Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem Hoppe-Seyler 377: 385-390
5. Calkins CC and Sloane BF (1995) Mammalian cysteine protease inhibitors: biochemical properties and possible roles in tumor progression. Biol Chem Hoppe-Seyler 376: 71-80
6. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF and Emmert-Buck MR (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25: 857-862
7. Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc 187: 187-220
8. Ebert W, Knoch H, Werle B, Trefz G, Muley Th and Spiess E (1994) Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res 14: 895-900
9. Elliot E and Sloane BF (1996) The cysteine protease cathepsin B in cancer. Perspect Drug Discovery Design 6: 12-32
10. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF, Liotta LA and Stetler-Stevenson WG (1994) Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 145: 1285-1290
11. Erdel M, Trefz G, Spiess E, Habermaas S, Spring H, Lah T and Ebert W (1990) Localization of cathepsin B in two human lung cancer cell lines. J Histochem Cytochem 38: 1313-1321
12. Fidler JJ (1974) Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res 34: 1074-1078
13. Hermanck P and Sobin L (1987) TNM Classification of Malignant Tumors, 4th edn. International Union against Cancer (UICC). Springer: Berlin
14. Higashiyama M, Doi O, Kodama K, Yokouchi H and Takeishi R (1991) The prognostic implications of the cathepsin R expression in pulmonary adenocarcinomas. An immunohistochemical study. (In Japanese) Jpn J Cancer Clin 37: 1151-1157
15. Higashiyama M, Doi O, Kodama K, Yokouchi H and Taleishi R (1993) Cathepsin B expression in tumour cells and laminin distribution in pulmonary adenocarcinoma. J Clin Pathol 46: 18-22
16. Honn KV, Timar J, Rozhin J, Bazaz R, Sameni M, Ziegler G and Sloane BF (1994) A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp Cell Res 214: 120-130
17. Hsu SM, Raine L, and Fanger H (1981) Use of avidin-biolin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580
18. Hughes SI, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB, Beer DG, Hanash S (1998) A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA 95: 12410-12415
19. Inoue T, Ishida T, Sugio K and Sugimachi K (1994) Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res 54: 6133-6136
20. Kaptan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
21. Kayser K and Gabius H-J (1997) Graph theory and the entropy concept in histochemistry. Theoretical considerations, application in histopathology and the combination with receptor-specific approaches. In: Progress in Histochemistry and Cytochemistry, Graumann W, Bendayan M, Bosman FT, Heitz PhU, Larsson L-I, Wolfe HJ (eds), Vol. 32, Gustav Fischer: Stuttgart, Jena, Lübeck, Ulm
22. Knoch H, Werle B, Ebert W and Spiess E (1994) Imbalance between cathepsin B and cysteine proteinase inhibitors is of prognostic significance in human lung cancer. Int J Oncol 5: 77-85
23. Kos J, ŠakSmid L, Krasovec M, Svetic B, Lenarcic B, Vrhovec I,Škrk J and Turk V (1995) Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe-Seyler 376: 401-405
24. Kos J, Štabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-lerala N and Vrhovec I (1997) Cathepsins B, H, L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3: 1815-1822
25. Kos J, Nielsen H-J, Krasovec M, Christensen H, Cimerman N, Stephens RW and Brünner N (1998) Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 4: 1511-1516
26. Krepela E, Kasafirek E, Novak K and Viklicky J (1990) Increased cathepsin B activity in human lung tumors. Neoplasma 37: 61-70
27. Lah T and Kos J (1998) Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 379: 125-130
28. Lah TT, Kokalj-Kunovar M, Štrukelj B, Pungerèar J, Barlic̀-Maganja D. Drobniè-Kosorok M, Kastelic L, Babnik J and Turk V (1992) Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 50: 36-44
29. Lah TT, Calaf G. Kalman E, Shinde BG, Somers R, Russo J, Jarocz D, Zabreckzy J and Daskal I (1995a) Cathepsins D, B and L in human breast carcinoma and in transformed cells. J Biol Chem Hopper-Seyler 376: 357-363
30. Lah TT, Hawlley M, Rock KI, and Goldberg AI, (1995b) Gamma-interferon causes selective induction of lysosomal proteases cathepsins B and L, in macrophages. EEBS Letters 262: 85-89
31. Lah TT, Kos J, Blejec A, Frkoviè-Georgio S, Golouh R, Vrhovec I and Turk V (1997) The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the diseasc. Pathology Oncology Research 3(2), 89-98
32. Ledakis P, Tester WT, Rosenberg N, Romero-Fischmann D, Daskal I and Lab TT (1996) Cathepsins D, B, and L in malignant human lung tissue. Clin Cancer Res 2: 561-568
33. Leto G. Tumminello FM, Pizzolanti G. Montaho G, Soresi M. Carroccio A, Ippolito S and Gebbia N (1997) Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas 14: 22-27
34. Manegold C and Drings P (1998) Chemotherapie des nichtkleinzclligen Lungenkarzinoms. In: Thoraxtamoren: Diagnoslik - Staging - gegenwürtiges Therapickonzept, Drings P, Vogt-Moykpf I (eds), pp. 310-327. Springer Verlag: Heidelberg, Germany
35. Mori M, Kohli A, Baker SP, Savas L, Fraire AE (1997) Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer are they useful? Mod Pathol 10: 572-577
36. Mantovani A (1990) Turnour associated macrophages. Curr Opin Immuonol 2: 689-692
37. Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF and Rosenblum MI. (1995) Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. Neurosurg 83: 285-290
38. Mountain CF (1991) Surgical treatment of lung cancer. Critic Res Oncol/Hematol 11: 179-207
39. Opdenakker G and Van Damme J (1992) Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Todav 13: 464-465
40. Ozeki Y, Takishima K, Takagi K, Aida S, Tarnai S, Mamiya G and Oagata T (1993) Immunohistochemical analysis of cathepsin B expression in human lung adenocarcinoma: the role in cancer progression. Jpn J Cancer Res 84: 972-975
41. Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, sameni M, Rozhin J, Ziegler G and Sloane BF (1994) Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54: 6027-6031
42. Rozhin J, Robinson D, Stevens MA, Lah TT, Honn KV, Ryan RE and Sloane BF (1987) Properties of a plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic B 16 mclanoma variants. Cancer Res 47: 6620-6628
43. Rozhin J. Samenin M, Ziegler G and Sloane BF (1994) Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54: 6517-6525
44. Schraube P, Kimming B, Latz D, Flentje M and Wannenmacher M (1998) Radiotherapie des Bronchialkarzinoms. In: Thoraxtumoren: Diagnostik - Staging - genenwörtiges Therapickonzept. Drings P, Vogt Moykopf I (eds), pp. 277-295. Springer Verlag: Heidelberg, Germany
45. Sedo A, Krepela E and Kasafirck E (1991) Dipeptidylpeptidase IV, prolylendopeptidase and cathepsin B activities in primary human lung tumors and lung parenchyma. J Cancer Res Clin Oncol 117: 249-253
46. Shuja S. Sheahan K and Murnanc MJ (1991) Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer 49: 341-346
47. Stoane BF, Rozhin J, Haifield JS, Crissman JD and Honn KV (1987) Plasma-membrane associated cysteine proteinases in human and animal tumors. Exp Cell Biol 55: 209-224
48. Stoane BF, Moin K, Sameni M, Tait LR, Rozhin J and Ziegler G (1994) Membrane associated of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci 107: 373-384
49. Stonelake PS, Jones CE, Neoptolemos JP and Baker PR (1997) Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 75: 951-959
50. Strohmaier A-R, Porwol T, Acker H and Spiess E (1997) Tomography of cells by confocal laser scanning microscopy and computer assisted three-dimensional image reconstruction: Localization of cathepsin B in tumor cells penetrating collagen gels in vitro. J Histochem Cytochem 45: 975-983
51. Sukoh N, Abe S, Ogura S, Isobe H, Takekawa H. Inoue K and Kawakami Y (1994a) Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer 74: 46-51
52. Sukoh N, Abe S, Nakajima I, Ogura S, Isobe H, Inoue K and Kawakami Y (1994b) Immunohistochemical distributions of cathepsin B and basement membrane antigens in human lung adenocarcinoma: association with invasion and metastasis. Virchows Arch 424: 33-38
53. Trefz G, Lüthgens K, Erdel M, Spiess E and Ebert W (1989) Plasminogen activator and cathepshin B in normal and malignant human lung tissue. J Cancer Res Clin Oncol 115: 550
54. Ulbrich B, Hagmann W, Ebert W and Spiess E (1996) Differential secretion of cathepsins B and L from normal and tumor human lung cells stimulated by 12(S)-hydroxy-cicosatetracnoic acid (12(S)-HETE). Exp Celt Res 226: 255-263
55. Umansky V, Rocha M, Kruger A, van Hoegen P and Schirrmacher V (1995) In situ activated macrophages are involved in bost resistance to lymphoma metastasis by production of nitric oxide. Int J Cancer 7: 33-40
56. Werle B, Ebert W, Klein W and Spiess E (1994) Cathepsin B in tumors, normal tissue and isolated cells from the human lung. Anticancer Res 14: 1169-1176
57. Werle B, Ebert W, Klein W and Spiess E (1996) Charge polymorphism in human lung cell procathepsin B. Anticancer Res 16: 19-54
58. Werle B, Jülke B, Lah T, Kos J, Spiess E and Ebert W (1997a) Cathepsin B and cathepsin L: prognostic factors in human lung cancer? In Proteolysis in Cell Function, Hopsu-Havu M, Jarvinen M, Kirschke H (eds), pp. 472-478, IOS Press: Amsterdam, The Netherlands
59. Werle B, Jülke B, Lab T, Spiess E and Ebert W (1997b) Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung. Br J Cancer 75: 1137-1143
60. World Health Organization (1981) Histological Classification of Lung Tumors. WHO: Geneva
61. Yan SQ, Sameni M and Sloane BF (1998) Cathepshin B and human tumor progression. Biol Chem 379: 113-123